Pembrolizumab is a novel cancer treatment drug that targets PD-1 receptors on cancer cells to stimulate the immune system to attack the tumor. It is a highly selective IgG4-kappa humanized monoclonal antibody. Approved by the FDA, it has shown promising results in treating various cancers, such as melanoma and HER2-positive breast and gastric cancers. It is typically administered intravenously at a dose of 2mg/kg every three weeks. However, like any medication, it may cause side effects such as digestive discomfort, fatigue, and skin reactions. Therefore, it's crucial to follow the doctor's instructions for safe and effective use.
